Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com

Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

By Jared Kaltwasser

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

By Giuliana Grossi

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Judy Alberto, MHA, RPh, BCOP, Community Oncology Alliance

April 5th 2024

Optimizing Formulary Management: COA's Judy Alberto Shares Insights

Judy Alberto, MHA, RPh, BCOP, director of clinical initiatives at the Community Oncology Alliance (COA), addresses the challenges pharmacies face in managing formularies to provide optimal patient care.

COA 2024 | Image credit: COA

April 4th 2024

Navigating the Community Oncology Relationship With the Local Hospital

A lawsuit that followed a health system revoking community oncologists' hospital privileges was the jumping off point for a discussion of how to manage this key relationship.

Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health

April 4th 2024

Dr Mila Felder Discusses Peer-to-Peer Support in Health Care Organizations

Hayden E. Klein Pearl Steinzor

Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, discusses the impact of peer support groups within a health care organization and its patients.

Emily Touloukian, DO, Coastal Cancer Center

April 1st 2024

2024 COA Community Oncology Conference Preview With Dr Emily Touloukian

With the 2024 Community Oncology Conference, from the Community Oncology Alliance (COA), set to kick off this week in Orlando, Florida, The American Journal of Managed Care® spoke with Emily Touloukian, DO, COA board member and 1 of 6 cochairs for this year’s meeting, on highlights from the packed agenda and the power of advocacy.

Will Shapiro

March 28th 2024

Will Shapiro Discusses the Impact of Large Language Models on Cancer Care

Hayden E. Klein Pearl Steinzor

Will Shapiro, vice president of data science at Flatiron Health, discusses opportunities to implement artificial intelligence in cancer care.

Physician holds hand of patient | C Davids/peopleimages.com - stock.adobe.com

March 28th 2024

Oncologists Find Ethical Challenges With Artificial Intelligence in Cancer Care

Explainability, consent, and responsibility are noted as challenges that may hinder implementation of artificial intelligence (AI) in cancer care, according to a new study.

Woman with magnifying glass showing mole and birthmark on her body for prevention of melanoma | Peakstock - stock.adobe.com

March 19th 2024

Skin Cancer Incidence Highest Among Rural, SOC Individuals

Posters presented at the American Academy of Dermatology 2024 Annual Meeting identified significant health disparities among patients living in rural areas and those with skin of color (SOC).

FDA approved| Image credit: wladimir1804 - stock.adobe.com

March 15th 2024

FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy

The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.

Help support advice guidance signpost | Image Credit: PX Media - stock.adobe.com

March 12th 2024

Navigating the Mental Health Challenges of Cancer Diagnosis, Treatment, and Survivorship

Stress has potential links to worse outcomes in cancer, such as decreased quality of life and greater risks of disease progression and metastasis. There is a complex mix of emotions patients with cancer experience.

Breast cancer with lymphatics - Axel Kock - stock.adobe.com.jpeg

March 5th 2024

Annual Breast Cancer Screening Should Begin at Age 40 Years, Study Finds

Modeling estimates indicate that annual breast cancer screening starting at age 40 years provides the greatest benefit to women and reduces risk per examination.

Doctor comforting a patient | Image credit: lenetsnikolai - stock.adobe.com

March 1st 2024

Treating the Whole Person in Cancer Care: Addressing Comprehensive Services

The session at ACCC's 50th Annual Meeting & Cancer Center Business Summit featured discussions on patient navigation, addressing patients' sexual health, needs of LGBTQ+ patients, and more.

Mila Felder, MD, FACEP

March 1st 2024

Dr Mila Felder Explains Advocate Health's Approach to Well-Being for the Postpandemic Oncology Workforce

Hayden E. Klein

Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, talks about tailoring the Stanford Model of Professional Fulfillment to support the postpandemic oncology workforce.

Cost Sharing for Oral Lenvatinib Among Commercially Insured Patients

March 1st 2024

Cost Sharing for Oral Lenvatinib Among Commercially Insured Patients

Margaret I. Liang, MD, MS Ling Chen, MD, MPH Emeline M. Aviki, MD, MBA Jason D. Wright, MD

Among a cohort of insured patients with cancer, the median total monthly cost of oral lenvatinib was $17,253, and 75% of patients paid $100 or less out of pocket per month for the drug.

February 29th 2024

QCCA, NCCA Merge to Form ONCare Among Independent Oncology Practices

ONCare Alliance will be led by 2 of the leading women in community oncology, cochairs Barbara McAneny, MD, of the New Mexico Cancer Center, and Sibel Blau, MD, of Northwest Medical Specialties, PLLC, of Puyallup, Washington.

February 29th 2024

What Are the Steps to Quality Improvement in Cancer Care?

Quality Improvement (QI) projects require a series of distinct steps and timely data collection that will allow clinics to see if changes are yielding results, a consultant told attendees at a preconference workshop at ACCC.

February 26th 2024

What We’re Reading: Alabama IVF Ruling Impacts; Administrative Task Fees; Nursing Shortage Response

Patients with cancer express shock and anxiety over the recent ruling by the Alabama Supreme Court regarding frozen embryos; doctors are beginning to charge fees for administrative tasks; some universities are implementing accelerated nursing programs to help with the shortage.

Blue folder with Cancer diagnosis | vchalup - stock.adobe.com

February 22nd 2024

COVID-19 Pandemic's Disruption on Cancer Detection in the US

A nationwide analysis reveals a significant drop in cancer diagnoses, highlighting an urgent need for a catch-up in screening efforts.

Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)

February 16th 2024

Kiana Mehring Discusses the Future of Value-Based Oncology Care

Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute, shares her thoughts on future directions in value-based oncology care and research.

Breast cancer - Axel Kock - stock.adobe.com.jpeg

February 14th 2024

Breast Cancer Incidence Highest Among Young Black Women in the US

Researchers have identified a surge in breast cancer rates among young women and racial disparities across age groups.

February 14th 2024

How Real-World Evidence Can Spur Collaboration and Changes in Oncology

Zhaohui Su, PhD

Chandler Cortina, MD, MS, FSSO, FACS | Image Credit: Froedtert & Medical College of Wisconsin

February 9th 2024

Getting to Know Dr Chandler Cortina, Breast Surgical Oncologist

Chandler Cortina, MD, MS, FSSO, FACS, is assistant professor of surgery and breast surgical oncologist at Froedtert & the Medical College of Wisconsin. His current research focuses on breast cancer risk not only in general but also among transgender and gender-diverse populations.

Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.

February 7th 2024

COA's Dr Miriam Atkins: PBMs, HR 5526, and Marketplace Strategy

Maggie L. Shaw Pearl Steinzor

Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance, discusses the impact of pharmacy benefit managers (PBMs) on health care costs and offers potential ways to remedy certain CMS decisions that negatively affect oncologists and their patients.

Blood sample test with positive diagnosis of thrombosis risk in a coagulation test | angellodeco - stock.adobe.com

February 2nd 2024

Risk of Venous Thromboembolism Increases After Cancer Surgery, Study Finds

The increased risk is likely due to the underlying cancer disease and adjuvant treatments, researchers find.

Enhertu (trastuzumab deruxtecan) product packaging | AstraZeneca photo

January 30th 2024

Priority Review Granted for Trastuzumab Deruxtecan; Would Be First Tumor-Agnostic ADC

A tumor-agnostic approval would be a significant development in the advance of antibody-drug conjugates (ADCs), which are designed to deliver a potent, cancer-fighting payload into a tumor while sparing nearby tissues.

Dr Lucy Langer

January 28th 2024

Dr Lucy Langer: How UnitedHealthcare Is Enhancing Oncology Pathway Adherence and Promoting Equity

Hayden E. Klein

UnitedHealthcare's oncology payment mode initially involved a pay-for-performance program based on pathways adherence, and will be transitioning in 2024 to a broader system with graded quartiles to incentivize greater participation and pathway adherence.

Samyukta Mullangi, MD, MBA | Image credit: X

January 22nd 2024

Dr Samyukta Mullangi Talks Cost Reductions, Scalability of Thyme Care's Navigation Program

Hayden E. Klein

The Thyme Care virtual navigation program demonstrated a $594 reduction in total costs per member per month for navigated cancer patients compared with a control group, emphasizing the scalability of the independent virtual navigation model across various contracts, with opportunities to adapt to different populations and needs in the evolving landscape of value-based care arrangements.

January 16th 2024

First-Line Tiragolumab With Atezolizumab Plus Chemo Improves PFS, OS in Patients With ESCC

Treatment with both PD-1 and TIGIT immunotherapy alongside chemotherapy demonstrated improved progression-free (PFS) and overall survival (OS) compared with chemotherapy alone in patients with esophageal squamous cell carcinoma (ESCC).

Kirollos Hanna | Image credit: LinkedIn

January 15th 2024

Dr Kirollos Hanna Talks Chemotherapy Shortage Challenges and Solutions

Hayden E. Klein

Especially during shortages, Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy services at Minnesota Oncology, says practices should carve out areas where going to a different therapeutic approach isn't considered off-pathway.

Doctor stacking wooden blocks with health care icons | image credit: REDPIXEL - stock.adobe.com

January 14th 2024

Navigating the Biosimilar Frontier: Opportunities and Challenges in 2024

Biosimilars offer substantial promise for a new era of accessibility and affordability for patients and the broader health care industry, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential in the US.

Pile of dollars and stethoscope | nata777_7 - stock.adobe.com

January 11th 2024

Substantial State Variations Identified in Health Insurance Coverage at Cancer Diagnosis

Health insurance coverage is a strong determinant of cancer care access and survival, and the observed variations are despite a significant increase in coverage under the Affordable Care Act.

...

6 7 8 9 10 11 12 13 14

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions